| Document |
Document Title |
|
WO/2007/102439A1 |
[PROBLEMS] To provide: a fractionation method for extracting an ingredient, particularly a pharmacologically active ingredient such as an iridoid compound, from an Eucommia ulmoides oliver leaf with good efficiency; a fractionation produ...
|
|
WO/2007/099915A1 |
It is intended to provide a highly safe antiviral agent originating in a plant, a food and a drink containing this antiviral agent and a medicine containing this antiviral agent as the active ingredient. Namely, an antiviral agent charac...
|
|
WO/2007/096137A1 |
The present invention provides new polyene macrolide derivatives which show very low toxicity while retaining high antifungal activity as compared with amphotericin B (AmB). These polyene macrolide derivatives comprise a polyene macrolid...
|
|
WO/2007/091393A1 |
[PROBLEMS] To provide a compound which has a novel structure and is effective against an influenza bacterium and an erythromycin-resistant bacterium (e.g., an erythromycin-resistant pneumococcal or streptococcal bacterium), as well as a ...
|
|
WO/2007/089149A2 |
This invention relates to novel analogs of the DNA-binding alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and their conjugates. The conjugates are de...
|
|
WO/2007/083594A1 |
It is intended to provide a laxative with a gentle cathartic action and reduced diarrhea episodes and a food containing the same. A laxative containing genkwanin 5-O-β-primeveroside as an active ingredient. A laxative containing iriflop...
|
|
WO/2007/082475A1 |
Novel ent-kaurene diterpene compound and its derivatives, their preparation methods and their use. ent-Kaurene diterpene in the present invention could be used as desired intermediates for preparing asymmetric organic compounds and medic...
|
|
WO/2007/082703A1 |
The present invention relates to a solvent-derived, cocoa extract comprising between 25 and 65% by weight of polyphenols, and uses thereof for improving a beer production process and the resulting beer product. The invention further rela...
|
|
WO/2007/080170A1 |
The invention relates to a crystalline form of 1´-(1-methylethyl)- 4´-[(2-fluoro-4- methoxyphenyl)methyl]-5´-methyl-1H-pyrazol-3´-O-β-D-gluco
pyranoside, to a method for the preparation thereof, as well as to the use thereof for pre...
|
|
WO/2007/080507A2 |
The invention relates to processes for the preparation of anhydrous azithromycin. The invention also relates to a one-pot process for the preparation of azithromycin without isolation of intermediates. The invention also relates to pharm...
|
|
WO/2007/077219A1 |
The present invention relates to stable amorphous 3-De[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L- ribohexopyranosy l)oxy]- 1 1 , 12-dideoxy-6-O-methy 1-3-oxo- 12,11 -[oxycarbonyl[[4-[4-(3-pyridinyl)- 1 H- imidazol-l-yl]butyl]imino]]erythro...
|
|
WO/2007/072800A1 |
Disclosed is a photosensitizing compound represented by the formula (I): (I) wherein R1 represents a hydrogen atom, a C1-12 alkyl group or a C1-12 alkoxy group; R2 represents a C1-12 alkyl group or a C1-12 alkoxy group; R3, R4, R5, R6, R...
|
|
WO/2007/069264A2 |
A method of testing the purity of a sample of Telithromycin or a pharmaceutical dosage form comprising Telithromycin, which method comprises assaying the said sample for the presence of compound A, B and D, wherein compound A is represen...
|
|
WO/2007/069555A1 |
Disclosed is a compound represented by the general formula (1) below or a pharmaceutically acceptable salt thereof. Also disclosed are a process for producing such a compound or a pharmaceutically acceptable salt thereof, and a pharmaceu...
|
|
WO/2007/067281A2 |
A method for demethylating the 3'-dimethylamino group of erythromycin compounds.
|
|
WO2007043710A9 |
Compounds represented by the general formula [I] (wherein each symbol is as defined in the description) or pharmacologically acceptable salts thereof; and pharmaceutical compositions containing the compounds or the salts as the active in...
|
|
WO/2007/062468A1 |
Compounds having useful biological activity, particularly antioxidant and anti-inflammatory activity, derived from Centipeda cunninghamii, and biologically active derivatives thereof, pharmaceutical compositions comprising these compound...
|
|
WO/2007/063335A2 |
The invention provides a salt of amphotericin B and meglumine in which the molar ratio of amphotericin B to meglumine is about 1:1.
|
|
WO/2007/060686A1 |
The present invention provides novel loganin analogues of formula (I) and a process for the preparation thereof. The present invention further provides the use of lridoid glycoside loganin isolated from the fruit pulp of Strychnos nux-vo...
|
|
WO2006056297A9 |
The invention relates to complexes of specific flavonoid derivatives of formula (I), wherein R1 and R2 are selected among H and OR11, OR11 independently representing OH, straight-chain or branched C1 to C20 alkyloxy groups, straight-chai...
|
|
WO/2007/060618A2 |
The present invention provides macrolide derivatives, which can be used as antibacterial agents. Compounds described herein can be used for treating or preventing conditions caused by or contributed to by gram-positive, gram-negative or ...
|
|
WO/2007/060518A2 |
Provided herein are ketolide derivatives, which can be used as antibacterial agents. Compounds described herein can be used for treating or preventing conditions caused by or contributed to by gram positive, gram negative or anaerobic ba...
|
|
WO/2007/059307A2 |
Provided is telithromycin which melts at a range of 175 °C to 185 °C. Also provided are solid states of telithromycin and processes for the preparation thereof.
|
|
WO/2007/054296A1 |
A compound of formula (I) or a pharmaceutically acceptable derivative thereof, having antimicrobial activity, processes for their preparation, compositions containing them and to their use in medicine.
|
|
WO/2007/054295A1 |
A compound of formula (I) and/or pharmaceutically acceptable derivatives thereof, having antimicrobial activity, processes for their preparation, compositions containing them and to their use in medicine.
|
|
WO/2007/053642A1 |
This invention relates to compositions, and methods of use thereof, containing polyphenols such as flavanols, procyanidins and derivatives thereof, for treating and preventing certain tumors/cancers, and more specifically to treating and...
|
|
WO/2007/050375A2 |
CCR5 antagonists having the following core structure Formula (I) (AA) are claimed, for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic der...
|
|
WO/2007/049296A2 |
The present invention relates to novel substantially amorphous Telithromycin and its process of preparation.
|
|
WO/2007/044927A2 |
The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions com...
|
|
WO2007003422A9 |
The present invention relates to macrolide compounds endowed with antiinflammatory activity and more particularly relates to new stable crystalline forms of a macrolide derivative with antiinflammatory activity, processes for the prepara...
|
|
WO/2007/039914A2 |
The present invention relates to novel polymorphs of Telithromycin designated as Form I, II and III and its process for preparation. Also it provides Telithromycin with at least 99% purity.
|
|
WO/2007/036951A2 |
The present invention provides a process for the preparation of 6-O-methylerythromycin A Form II comprising treating 6-O-methylerythromycin A with organic acid selected form trifluoroacetic acid, para-toluene sulphonic acid, oxalic acid ...
|
|
WO/2007/035116A1 |
A method of localising reproduction assisting hyaluronic acid to reproductive cell surfaces by covalently linking it to lipids is disclosed.
|
|
WO/2007/029266A2 |
The invention relates to a process for preparing θ-Deoxo-θa-aza-θa-homoerythromycin A of formula (III), which is an intermediate in the preparation of Azithromycin dihydrate.
|
|
WO/2007/029265A2 |
The present invention discloses a process for preparing Clarithromycin, comprising selectiviely methylating a 2'I4"-O-bis(trimethylsilyl)erythromycin A 9-[O-(1-methoxy-1- methylethyl)oxime] of formula (II) with methylating agent comprisi...
|
|
WO/2007/025089A2 |
The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti- infective, antiproliferative, anti-inflammatory, and prokinetic agents. These compounds ar...
|
|
WO/2007/023774A1 |
Disclosed is an agent for amelioration of impaired ophthalmic arterial blood flow. Also disclosed is a method for amelioration of impaired ophthalmic arterial blood flow. An agent for amelioration of impaired ophthalmic arterial blood fl...
|
|
WO/2007/025284A1 |
The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti- infective, anti-proliferative, anti-inflammatory, and prokinetic agents. The compounds hav...
|
|
WO/2007/021721A2 |
Compositions and methods are provided related to Pseudomonas bacteria. The compositions and methods may be used for diagnosis and therapy of medical conditions involving infection with Pseudomonas bacteria. Such infections include Pseudo...
|
|
WO/2007/017898A2 |
A process of recovery of Pt/C catalyst from the hydrogenation of 6,9-Imino ether is carried out by isolating spent Pt/C by filtration, reactivating the wet spent Pt/C catalyst by treating the spent Pt/C with strong acid like perchloric a...
|
|
WO/2007/014895A2 |
The invention relates to methods for preventing or treating metabolic disorders, for improving glycemic control, for preventing progression from impaired glucose tolerance, insulin resistance and/or from metabolic syndrome to type 2 diab...
|
|
WO/2007/015265A2 |
A process for preparing 6,9-lmino ether from Erythromycin thiocyanate without isolating Erythromycin base and Erythromycin oxime and Beckmann's rearrangement of erythromycin oxime is carried in the presence biphasic solvent system compri...
|
|
WO/2007/012464A1 |
The present invention relates to macrolide conjugates of pyrrolizine and indolizine derivatives with macrocyclic antibiotics and derivatives thereof. The macrolide conjugates are potent inhibitors of 5-lipoxygenase and cyclooxygenase and...
|
|
WO/2007/010015A1 |
The present invention relates to processes for preparing the compounds of general formula I, wherein the groups R1 to R6 and R7a, R7b, R7c are defined according to claim 1. Furthermore the present invention relates to processes for prepa...
|
|
WO2006124720B1 |
Daunorubicin ("DNR") compounds synthesized with uncommon sugars exhibit enhanced effectiveness in treating various drug-resistant cancers.
|
|
WO/2007/007148A1 |
The present invention relates to a process of forming amorphous azithromycin comprises the steps of forming a solution comprising azithromycin and a solvent, atomizing the solution, followed by evaporating at least a portion of the solve...
|
|
WO/2007/004621A1 |
[PROBLEMS] To provide a novel anti-cancer agent having a reduced cytotoxicity. [MEANS FOR SOLVING PROBLEMS] A compound represented by the chemical formula 1 or a salt thereof. This compound has an organic group introduced into a given ke...
|
|
WO/2006/136945A1 |
Metabolites of 1 -[6-(1 -ethyl-1 -hydroxy-propyl)-pyridin-3-yl]-3-[2-(4-methyl-piperazin-1 - yl)-benzyl]-pyrrolidin-2-one, and use of same. Metabolites of the present invention are as shown in Formula (II): (II) wherein R1, R2 and R3 are...
|
|
WO/2006/137423A1 |
A method for administration of clarithromycin or a salt thereof to a mammal for the treatment and/or prevention of a pulmonary disease induced by the destruction of pulmonary alveoli which is caused by smoking, air pollution, a harmful g...
|
|
WO/2006/135083A1 |
Disclosed are a pharmaceutical for the prevention or treatment of visceral fat syndrome and a beverage/food for the prevention or amelioration of the disease. A prophylactic or therapeutic agent for visceral fat syndrome comprising luteo...
|
